Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic Bevacizumab in Neovascular AMD (BEAT-AMD)
NCT00531024Phase 3Completed
- Sponsor
- Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
- Start
- Aug 2005
- Primary completion
- Jan 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Exudative Neovascular Age-Related Macular Degeneration (nAMD) comparing Bevacizumab with Placebo (2 arms). Primary endpoint: Lesion size at 6 months. Started Aug 2005; status: completed.
02
Drugs
bevacizumab
03
Conditions
Exudative Neovascular Age-Related Macular Degeneration (nAMD)
Beyond the preview
Go deeper on NCT00531024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00531024.